Editorial: vedolizumab as a treatment and cause of extra‐intestinal manifestations of inflammatory bowel disease

Abstract

Conversely, however, 13.8% of those without joint involvement at baseline developed joint pain, albeit mostly arthralgia rather than frank arthritis, and 4.8% had paradoxical skin manifestations. The paradoxical occurrence of joint symptoms with vedolizumab has been reported previously in case series and is not unique to this drug having been reported with anti-TNF therapies. 5,6 Likewise, cutaneous adverse effects such as psoriaform lesions and eczema are recognised with anti-TNF drugs with a similar rate as seen in this study with vedolizumab. 7 It is not yet clear whether these adverse manifestations relate mostly to the specific actions of both types of drug including the balance of cytokines, or are non-specific and due more to their monoclonal antibody structure and potential for induction of autoantibodies. Distinguishing these mechanisms will be important for the future of monoclonal antibody drugs.

Extra Intestinal Manifestations in Children with Inflammatory Bowel Disease, A Single Center Report from Iran

“…The frequency of EIM in IBD has been reported from 16-40% (19)(20)(21)(22) with musculoskeletal (including arthritis, ankylosing spondylitis) and cutaneous presentations (including erythema nodosum, pyoderma gangrenosum) are among the most common observed conditions reported in as high as 50% of the patients in previous reports (19,21,23,24). EIMs in IBD are associated with significant morbidities and lowering the quality of life status (25).…”

Editorial: Monitoring methotrexate polyglutamates in Crohn's disease—Authors' reply

“…We thank Drs. Barclay and Stamp for their editorial 1 discussing our recent publication 2 . Prior to this publication, we conducted a meta‐analysis across immune‐mediated inflammatory diseases (IMIDs) confirming the association between methotrexate polyglutamates (MTX‐PGs) in red blood cells (RBCs) and treatment efficacy 3 .…”